Iron deficiency in heart failure and cardiovascular diseases – from pathophysiology to modern strategies
References
- Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Lüscher, TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125–33; DOI:10.1002/ejhf.823.
- Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, DesvigneNickens P, Butler J, Braunwald E. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317(19):1958–66; DOI:10.1001/jama.2017.5427.
- Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–68; DOI:10.1093/eurheartj/ehu385.
- von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019;7(1):36–46; DOI:10.1016/j.jchf.2018.07.015.
- Sagar P, Angmo S, Sandhir R, Rishi V, Yadav H, Singhal NK. Effect of hepcidin antagonists on anemia during inflammatory disorders. Pharmacol Ther. 2021;226:107877; DOI:10.1016/j.pharmthera.2021.107877.
- de las Cuevas Allende R, Díaz de Entresotos L, Conde Díez S. Anaemia of chronic diseases: pathophysiology, diagnosis and treatment. Med Clin (Barc). 2021;156(5):235–42; DOI:10.1016/j.medcli.2020.07.035.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599–726; DOI:10.1093/eurheartj/ehab368.
- Auerbach M, Deloughery TG, Tirnauer JS. Iron deficiency in adults: a review. JAMA. 2025;333(20):1813–23; DOI:10.1001/JAMA.2025.0452.
- Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, Van Der Wal HH, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK, Vellenga E, Mariani MA, de Boer RA, van Veldhuisen DJ, van der Meer P. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11(2):e004519; DOI:10.1161/CIRCHEARTFAILURE.117.004519.
- Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, Inciardi RM, Clark AL. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol. 2022;79(4):341–51; DOI:10.1016/j.jacc.2021.11.039.
- Graham FJ, Masini G, Pellicori P, Cleland JGF, Greenlaw N, Friday J, Kazmi S, Clark AL. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. Eur J Heart Fail. 2022;24(5):807–17; DOI:10.1002/ejhf.2251.
- Maeder MT, Khammy O, Dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure: implications for anemia accompanying heart failure. J Am Coll Cardiol. 2011;58(5):474–80; DOI:10.1016/j.jacc.2011.01.059.
- Graham FJ, Pellicori P, Kalra PR, Ford I, Bruzzese D, Cleland JGF. Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail. 2023;25(4):528–37; DOI:10.1002/ejhf.2810.
- Sirbu O, Tirnoveanu A, Haliga RE, Sorodoc V, Sava M, Bologa C, Petris OR, Morarasu BC, Diaconu AD, Ceasovschih A, Lionte C, Morariu PC, Morariu BA, Statescu C, Sascau RA, Floria M, Sorodoc L. Iron deficiency in heart failure: from ESC guidelines to clinical practice at a Romanian hospital. Biomedicines. 2025;13(9):2296; DOI:10.3390/biomedicines13092296.
- Barandiara n Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, Henkens MTHM, Weerts J, Spanjers MHA, Knackstedt C, van Empel VPM. Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Fail. 2021;8(2):1304–13; DOI:10.1002/ehf2.13204.
- Savarese G, von Haehling S, Butler J, Cleland JGF, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Eur Heart J. 2023;44(1):14–27; DOI:10.1093/eurheartj/ehac569.
- Albulushi A, Kashoub M, Al-Saidi K, Al-Farhan H. Iron deficiency in pulmonary hypertension implications, supplementation, and future directions. Int Heart J. 2024;65(4):593–600; DOI:10.1536/ihj.24-055.
- Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O’Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023;389(11):975–86; DOI:10.1056/nejmoa2304968.
- Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, Metra M, Bo hm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–83; DOI:10.1161/CIRCULATIONAHA.117.027497.
- Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, CominColet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895–1904; DOI:10.1016/S0140-6736(20)32339-4.
- Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, Van Veldhuisen DJ, Roubert B, Blackman N, Friede T, Jankowska EA, Anker SD. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023;44(48):5077–91; DOI:10.1093/eurheartj/ehad586.
- Martens P, Dupont M, Dauw J, Nijst P, Herbots L, Dendale P, Vandervoort P, Bruckers L, Tang WHW, Mullens W. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial. Eur Heart J. 2021;42(48):4905–14; DOI:10.1093/eurheartj/ehab411.
- Karavidas A, Troganis E, Lazaros G, Balta D, Karavidas IN, Polyzogopoulou E, Parissis J, Farmakis D. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study. Eur J Heart Fail. 2021;23(4):593–7; DOI:10.1002/ejhf.2092.
- Cheema B, Chokshi A, Orimoloye O, Ardehali H. Intravenous iron repletion for patients with heart failure and iron deficiency: JACC state-of-the--art review. J Am Coll Cardiol. 2024;83(25):2674–89; DOI:10.1016/J. JACC.2024.03.431.
- Gao G, Li J, Zhang Y, Chang YZ. Cellular iron metabolism and regulation. Adv Exp Med Biol. 2019;1173:21–32; DOI:10.1007/978-981-13-9589-5_2.
- Frazer DM, Anderson GJ. The regulation of iron transport. Biofactors. 2014;40(2):206–14; DOI:10.1002/BIOF.1148.
- Ganz T. Anemia of Inflammation. N Engl J Med. 2019;381(12):1148–57; DOI: 10.1056/NEJMra1804281.
- Ferreira JP, Anker SD, Butler J, Filippatos G, Januzzi JL, Schueler E, Panova-Noeva M, Wetzel K, Prochaska J, Pocock SJ, Sattar N, Sumin M, Zannad F, Packer M. Effect of empagliflozin on the mechanisms driving erythropoiesis and iron mobilization in patients with heart failure: The EMPEROR program. J Am Coll Cardiol. 2025;85(18):1757–70; DOI:10.1016/J. JACC.2025.03.503.
- Papalia F, Jouhra F, Amin-Youssef G, Shah AM, Charles-Edwards G, Okonko DO. Cardiac energetics in patients with chronic heart failure and iron deficiency: an in-vivo 31 P magnetic resonance spectroscopy study. Eur J Heart Fail. 2022;24(4):716–23; DOI:10.1002/EJHF.2454.
- Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018;20(5):910–9; DOI:10.1002/EJHF.1154.
- Rineau E, Gaillard T, Gueguen N, Procaccio V, Henrion D, Prunier F, Lasocki S. Iron deficiency without anemia is responsible for decreased left ventricular function and reduced mitochondrial complex I activity in a mouse model. Int J Cardiol. 2018;266:206–12; DOI:10.1016/J. IJCARD.2018.02.021.
- Corradi F, Masini G, Bucciarelli T, De Caterina R. Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives. Cardiovasc Res. 2023;119(14):2405–20; DOI:10.1093/CVR/CVAD146.
- Sato T, Chang HC, Bayeva M, Shapiro JS, Ramos-Alonso L, Kouzu H, Jiang X, Liu T, Yar S, Sawicki KT, Chen C, Martínez-Pastor MT, Stumpo DJ, Schumacker PT, Blackshear PJ, Ben-Sahra I, Puig S, Ardehali H. mRNA-binding protein tristetraprolin is essential for cardiac response to iron deficiency by regulating mitochondrial function. Proc Natl Acad Sci U S A. 2018;115(27):E6291–E6300; DOI:10.1073/PNAS.1804701115.
- Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flögel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J. 2017;38(5):362-72; DOI:10.1093/EURHEARTJ/EHW333.
- Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, Ponikowski P. Identification of three mechanistic pathways for iron-deficient heart failure. Eur Heart J. 2024;45(26):2281–93; DOI:10.1093/EURHEARTJ/EHAE284.
- Del Buono MG, Arena R, Borlaug BA, Carbone S, Canada JM, Kirkman DL, Garten R, RodriguezMiguelez P, Guazzi M, Lavie CJ, Abbate A. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(17):2209–25; DOI:10.1016/J.JACC.2019.01.072.
- World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/9789240000124/.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bo hm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44(37):3627–39; DOI:10.1093/eurheartj/ehad195.
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032; DOI:10.1161/CIR.0000000000001063.
- Cohen-Solal A, Philip JL, Picard F, Delarche N, Taldir G, Gzara H, Korichi A, Trochu JN, Cacoub P. Iron deficiency in heart failure patients: the French CARENFER prospective study. ESC Heart Fail. 2022;9(2):874–84; DOI:10.1002/ehf2.13850.
- Padda I, Sebastian SA, Fabian D, Sethi Y, Johal G. The efficacy and safety of ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency: an updated systematic review and metaanalysis of randomized controlled trials. Diseases. 2024;12(12):339; DOI:10.3390/diseases12120339.
- Dhaliwal S, Kalogeropoulos AP. Markers of iron metabolism and outcomes in patients with heart failure: a systematic review. Int J Mol Sci. 2023;24(6):5645; DOI:10.3390/ijms24065645.
- Graham FJ, Masini G, Lakhal-Littleton S, Clark AL, Cleland JGF, Pellicori P. Iron deficiency in cardiovascular disease – diagnosis, clinical implications, and future directions. Circ J. 2025; DOI:10.1253/circj.cj-25-0220.
- Von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Derad C, Diek M, Karakas M, Birkemeyer R, Fillippatos G, Lainscak M, Butler J, Ponikowski P, Böhm M, Friede T, Anker SD. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIRHFpEF trial. Eur Heart J. 2024;45(37):3789–3800; DOI:10.1093/eurheartj/ehae479.
- Karakas M, Friede T, Butler J, Talha KM, Placzek M, Asendorf T, Diek M, Nosko A, Stas A, Kluge S, Jarczak D, DeHeer G, Rybczynski M, Bayes-Genis A, Böhm M, Coats AJS, Edelmann F, Filippatos G, Hasenfuß G, Haverkamp W, Lainscak M, Landmesser U, Macdougall IC, Merkely B, Pieske BM, Pinto FJ, Rassaf T, Visser-Rogers JK, Rosano G, Volterrani M, von Haehling S, Anker MS, Doehner W, Ince H, Koehler F, Savarese G, Khan MS, Kröhnert UR, Gori T, Trenkwalder T, Akin I, Paitazoglou C, Kobielusz-Gembala I, Kuthi L, Frey N, Licka M, Kääb S, Laugwitz KL, Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): sexspecific outcomes. Eur J Heart Fail. 2025;27(11):2328–42; DOI:10.1002/ejhf.3742.
- Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199–209; DOI:10.1016/S0140-6736(22)02083-9.
- Alnuwaysir RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, Gomez KA, van der Wal HH, Cleland JGF, Dickstein K, Lang CC, Ng LL, Ponikowski P, Anker SD, van Veldhuisen DJ, Voors AA, van der Meer P. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2022;24(1):192–204; DOI:10.1002/ejhf.2393.
- Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50; DOI:10.1182/blood-2018-06-856500.
- Silva C, Martins J, Campos I, Arantes C, Braga CG, Salome N, Gaspar A, Azevedo P, A lvares Pereira M, Marques J, Vieira C. Prognostic impact of iron deficiency in acute coronary syndromes. Rev Port Cardiol (Eng Ed). 2021;40(8):525–36; DOI:10.1016/J.REPCE.2020.09.005.
- Misiewicz A, Badura K, Matuszewska-Brycht O, Krekora J, Drożdż J. Iron deficiency as a factor of worse prognosis in patients with acute myocardial infarction. Biomedicines. 2025;13(4):769; DOI:10.3390/biomedicines13040769.
- Liu Y, Clarke R, Bennett DA, Zong G, Gan W. Iron status and risk of heart disease, stroke, and diabetes: a Mendelian randomization study in European adults. J Am Heart Assoc. 2024;13(6):e031732; DOI:10.1161/JAHA.123.031732.
- Quatredeniers M, Mendes-Ferreira P, Santos-Ribeiro D, Nakhleh MK, Ghigna MR, Cohen-Kaminsky S, Perros F. Iron deficiency in pulmonary arterial hypertension: a deep dive into the mechanisms. Cells. 2021;10(2):477; DOI:10.3390/cells10020477.
- Lan M, Wu S, Fernandes TM. Iron deficiency and pulmonary arterial hypertension. Nutr Clin Pract. 2022;37(5):1059–73; DOI:10.1002/ncp.10884.
- Repsold L, Harutyunova S, Grünig E, Benjamin N, Xanthouli P, Egenlauf B, Florea A, Shaukat M, Sparla R, Mertens C, Muckenthaler MU, Eichstaedt CA. Reduced gastrointestinal iron uptake in pulmonary arterial hypertension: a prospective cross-sectional study. Respir Res. 2026;27(1):159; DOI:10.1186/s12931-026-03592-8.
- Howard LSGE, He J, Watson GMJ, Huang L, Wharton J, Luo Q, Kiely DG, Condliffe R, Pepke-Zaba J, Morrell NW, Sheares KK, Ulrich A, Quan R, Zhao Z, Jing X, An C, Liu Z, Xiong C, Robbins PA, Dawes T, de Marvao A, Rhodes CJ, Richter MJ, Gall H, Ghofrani HA, Zhao L, Huson L, Wilkins MR. Supplementation with iron in pulmonary arterial hypertension two randomized crossover trials. Ann Am Thorac Soc. 2021;18(6):981–8; DOI:10.1513/AnnalsATS.202009-1131OC.
- Van Empel VPM, Lee J, Williams TJ, Kaye DM. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2014;23(3):287–92; DOI:10.1016/j.hlc.2013.08.007.
- J V, Ashwaq M, Balachandra G. Study of prevalence of pulmonary arterial hypertension in iron deficiency anaemia and vitamin B12 deficiency anemia. Eur J Cardiovasc Med. 2025;15(8):391–5; DOI:10.61336/EJCM/25-08-74.
- Frei I, Gogniat AL, Buser A, Bolliger D. Anemia and iron deficiency in cardiac surgery patients: prevalence, implications, and therapeutic considerations. J Clin Med. 2025;14(22):8261; DOI:10.3390/jcm14228261.
- Tibi P, McClure RS, Huang J, Baker RA, Fitzgerald D, Mazer CD, Stone M, Chu D, Stammers AH, Dickinson T, Shore-Lesserson L, Ferraris V, Firestone S, Kissoon K, Moffatt-Bruce S. STS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management. Ann Thorac Surg. 2021;112(3):981–1004; DOI:10.1016/j.athoracsur.2021.03.033.
- Franchini M, Marano G, Veropalumbo E, Masiello F, Pati I, Candura F, Profili S, Catalano L, Piccinini V, Pupella S, Vaglio S, Liumbruno GM. Patient blood management: a revolutionary approach to transfusion medicine. Blood Transfus. 2019;17(3):191-5; DOI:10.2450/2019.0109-19.
- Shah A, Sugavanam A, Reid J, Palmer AJ, Dickson E, Brunskill S, Doree C, Oliver CM, Acheson A, Baikady RR, Bampoe S, Litton E, Stanworth S. Risk of infection associated with intravenous iron preparations: protocol for updating a systematic review. BMJ Open. 2019;9(6):e024618; DOI:10.1136/bmjopen-2018-024618.
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Ra degran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618–731; DOI:10.1093/eurheartj/ehac237.
- Hanna-Rivero N, Tu SJ, Elliott AD, Pitman BM, Gallagher C, Lau DH, Sanders P, Wong CX. Anemia and iron deficiency in patients with atrial fibrillation. BMC Cardiovasc Disord. 2022;22(1):204; DOI:10.1186/s12872-022-02633-6.
- Mei Z, Chen J, Luo S, Jin L, Liu Q, Chen Y. Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: a network meta-analysis of randomized controlled trials. Pharmacol Res. 2022;182:106345; DOI:10.1016/j. phrs.2022.106345.
- DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142(1):8–12; DOI:10.1159/000496966.
- Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020;75:100862; DOI:10.1016/j. mam.2020.100862.
- Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J, Weiss G. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–6; DOI:10.3324/haematol.2014.111492.
DOI: https://doi.org/10.2478/acb-2026-0003 | Journal eISSN: 2544-3577 (formerly 2080-2218)
Language: English
Page range: 20 - 29
Submitted on: May 4, 2026
Accepted on: Jun 20, 2026
Published on: Jul 20, 2026
Published by: Foundation for Cell Biology and Molecular Biology
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Julia Kubiak, Szymon Biegała, Mateusz Dudek, Kornel Jarosz, Zofia Konieczna, Magdalena Kuchta, Julia Papierkowska, Szymon Pieczara, published by Foundation for Cell Biology and Molecular Biology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.